Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.70 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | TSPO | P30536 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL9835197 | 0.94 | ALOX5 (0.64) | ALOX5PTGS1PTGS2RIPK1NPC1 | |
| SCHEMBL9707312 | 0.88 | PTGS1 (0.62) | ALOX5PTGS1PTGS2RIPK1LMNA | |
| SCHEMBL3279004 | 0.84 | ALOX5 (0.60) | ALOX5PTGS1PTGS2RIPK1NPC1 | |
| SCHEMBL9707420 | 0.84 | ALOX5 (0.70) | ALOX5PTGS1PTGS2KMT2AMEN1 | |
| SCHEMBL9707326 | 0.83 | ALOX5 (0.57) | ALOX5PTGS1PTGS2RIPK1NPC1 | |
| SCHEMBL9707249 | 0.83 | ALOX5 (1.00) | ALOX5PTGS1PTGS2TSPOALDH1A1 | |
| SCHEMBL628573 | 0.82 | RIPK1 (0.53) | ALOX5PTGS1PTGS2RIPK1NPC1 | |
| SCHEMBL11127626 | 0.80 | ALOX5 (0.56) | ALOX5PTGS1PTGS2RIPK1NPC1 | |
| SCHEMBL2526727 | 0.80 | LMNA (0.57) | ALOX5PTGS1PTGS2RIPK1NPC1 | |
| SCHEMBL2117209 | 0.80 | LMNA (0.62) | NPC1RAB9ACA12CA9TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030215781-A1 | Protective solutions for organs | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2003-11-20 | — | — | US | claimed |
| EP-1362511-A1 | Protective solution for preventing ischaemia | Dr. Franz Köhler Chemie GmbH (DE) | 2003-11-19 | — | — | EP | claimed |
| EP-0250530-A1 | NEW ARYL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-01-07 | — | — | EP | claimed |
| WO-1987004152-A1 | NEW ARYL DERIVATIVES | THE WELLCOME FOUNDATION LTD. (GB) | 1987-07-16 | — | — | WO | claimed |
| US-9603354-B2 | Protective solutions for organs | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-7977383-B2 | Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| EP-1362511-B1 | Protective solution for preventing ischaemia | KOEHLER CHEMIE DR FRANZ (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| EP-1859679-B1 | Protective solution for preventing ischaemia damage | KOEHLER CHEMIE DR FRANZ (DE) | 2009-10-28 | — | — | EP | disclosed |
| EP-1435962-A4 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS INC (US) | 2009-04-15 | — | — | EP | disclosed |
| CN-1281436-A | N-Benzyl-3-indenylacetamides derivatives for treating neoplasia | CELL PATHWAYS INC (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6166053-A | Substituted condensation products of N-benzyl-3-idenylacetamides with heterocyclic aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1044187-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | OSI Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| US-6066634-A | PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-5948779-A | APOPTOSIS; ANTICANCER AGENT | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999031065-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | CELL PATHWAYS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0250530-A1 | NEW ARYL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-01-07 | — | — | EP | disclosed |
| WO-1987004152-A1 | NEW ARYL DERIVATIVES | THE WELLCOME FOUNDATION LTD. (GB) | 1987-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | ALOX5 476/4885PTGS1 836/4885PTGS2 922/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | ALOX5 395/4885PTGS1 626/4885PTGS2 815/4885 |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | ALOX5 704/4885PTGS1 1332/4885PTGS2 2155/4885 |
| US-20030215781-A1 | Protective solutions for organs | GLS, CA1, SI | ALOX5 2508/4885PTGS1 694/4885PTGS2 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.